Ambiguous recommendations for preventive services are causing confusion among plans and providers on the clinically recommended preventive services that should be covered without cost sharing. A recent USPSTF recommendation on HIV prevention offers an opportunity to urge a recommending body to provide further clarity in its recommendation. Comments are due December 26.
Avalere is excited to join the CQMC as quality measurement experts in an effort to further inform a discussion focused on core measure sets to assess the quality of American healthcare.
Check out the second interview in our series on new supplemental benefits offered through Medicare Advantage plans for 2019; Kenny Kan and Erica Breese discuss the "rule of 8."
New Avalere analysis finds that beneficiaries enrolled in Employer Group Waiver Plans (EGWPs) have lower out-of-pocket (OOP) costs for select drugs than beneficiaries enrolled in other types of Part D plans.
Avalere analysis finds that most of the payment reductions from the proposed International Pricing Index Model for Part B drugs would affect oncologists, rheumatologists, and ophthalmologists.
As part of the Robert Wood Johnson Foundation Cost Conversation projects, Avalere led the development of a set of practice briefs that provide actionable resources to healthcare providers about how to improve the value and frequency of cost conversations with patients.
Over the past several years, Avalere has collaborated with the Academy of Nutrition and Dietetics to establish and support the Malnutrition Quality Improvement Initiative (MQii).
In the last interview of our mid-term elections series, Avalere experts Chris Sloan and Elizabeth Carpenter discuss potential implications on health policy.
Avalere experts, Chris Sloan and Tiernan Meyer, discuss potential state and federal-level scenarios for Medicaid expansion.
In the first interview in our 3-part series covering the mid-term elections and potential implications on health policy, Avalere expert Chris Sloan explores potential implications of the mid-term elections on health policy. To kick off the series, Avalere Founder, Dan Mendelson, discusses pre-existing conditions.
New Avalere research finds that health plan members enrolled in plans that cover abuse-deterrent formulations (ADFs) of opioids have a lower risk of opioid abuse (OA) and overdose (OD) and lower opioid abuse-related hospitalizations than people in plans that do not offer coverage of ADF opioids.
Shift in clinical practice as far back as 30 years ago planted the seeds for the current opioid epidemic. New research by Avalere Health finds that between the mid-1980s and 1990s, individual pharmaceutical manufacturers, national scientific bodies, and professional societies began a push to treat pain more aggressively.
New analysis from Avalere finds that 2.7 million individuals from states that have not expanded Medicaid could gain Medicaid coverage should their newly elected governors decide to expand the program or states pass expansion referenda on their ballots.
Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.
In episode 1 of our series Fred Bentley, Sean Creighton, and Kenny Kan discuss the new supplemental benefits offered through Medicare Advantage plans for 2019.
New Avalere study entitled “Using Aggregate Data to Proxy Individual-Level Socioeconomic Characteristics in Research on Medication Adherence: 9-Digit ZIP Code vs. Census Block Group” selected for the AMCP Foundation Best Poster Award at AMCP Nexus 2018.
Our analysis finds there will be winners and losers at the plan level under the new models.
With the 2018 mid-term elections weeks away, polls show healthcare is a top issue on the minds of voters.
Join Avalere experts for our analysis of CMS’ 2019 Star Ratings and a look at what’s to come for 2020 on our webinar on November 1, 2018.
MA plans expand coverage of supplemental benefits following administration’s policy change.
